Progress in classification and treatment for TNF receptor-associated periodic syndrome

Hiroshi Tsukamoto, Naoyasu Ueda, Takahiko Horiuchi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

TNF receptor-associated periodic syndrome (TRAPS) is an autosomal dominant autoinflammatory disorder characterized by recurrent febrile attacks. TRAPS is associated with mutation in the gene encoding TNF Receptor I (TNFRI) and seven mutations have been reported in Japan. Molecular modeling experiments indicate that the mutant TNFRI accumulates intracellularly in the endoplasmic reticulum due to misfolding and activates MAP kinase (MAPK) through induction of mitochondrial reactive oxygen species production. MAPK activation is further enhanced by the stimulation through toll-like receptor, resulting in the enhanced proinflammatory cytokine production. Febrile attacks last 21 days on average and occur every one to several months. Myalgia, erythematous macular rash, abdominal pain, conjunctivitis, periorbital edema, chest pain and arthralgia are commonly seen during the attacks. Glucocorticoid is effective in decreasing the severity and duration of the febrile attacks. Soluble TNF receptor etanercept, IL-1 receptor antagonist Anakinra TM and IL-6 receptor antagonist tocilizumab are effective in some patients. Japanese study group of TRAPS conducted national survey to make new diagnostic criteria in 2010.

Original languageEnglish
Pages (from-to)361-368
Number of pages8
JournalJapanese Journal of Clinical Immunology
Volume34
Issue number5
DOIs
Publication statusPublished - Nov 9 2011

Fingerprint

Tumor Necrosis Factor Receptors
Fever
Phosphotransferases
Interleukin 1 Receptor Antagonist Protein
Interleukin-6 Receptors
Mutation
Conjunctivitis
Interleukin-1 Receptors
Toll-Like Receptors
Myalgia
Arthralgia
Exanthema
Chest Pain
Endoplasmic Reticulum
Abdominal Pain
Glucocorticoids
Reactive Oxygen Species
Edema
Japan
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Progress in classification and treatment for TNF receptor-associated periodic syndrome. / Tsukamoto, Hiroshi; Ueda, Naoyasu; Horiuchi, Takahiko.

In: Japanese Journal of Clinical Immunology, Vol. 34, No. 5, 09.11.2011, p. 361-368.

Research output: Contribution to journalArticle

@article{5ad77d0dc7884b8682b453d6bce10c4b,
title = "Progress in classification and treatment for TNF receptor-associated periodic syndrome",
abstract = "TNF receptor-associated periodic syndrome (TRAPS) is an autosomal dominant autoinflammatory disorder characterized by recurrent febrile attacks. TRAPS is associated with mutation in the gene encoding TNF Receptor I (TNFRI) and seven mutations have been reported in Japan. Molecular modeling experiments indicate that the mutant TNFRI accumulates intracellularly in the endoplasmic reticulum due to misfolding and activates MAP kinase (MAPK) through induction of mitochondrial reactive oxygen species production. MAPK activation is further enhanced by the stimulation through toll-like receptor, resulting in the enhanced proinflammatory cytokine production. Febrile attacks last 21 days on average and occur every one to several months. Myalgia, erythematous macular rash, abdominal pain, conjunctivitis, periorbital edema, chest pain and arthralgia are commonly seen during the attacks. Glucocorticoid is effective in decreasing the severity and duration of the febrile attacks. Soluble TNF receptor etanercept, IL-1 receptor antagonist Anakinra TM and IL-6 receptor antagonist tocilizumab are effective in some patients. Japanese study group of TRAPS conducted national survey to make new diagnostic criteria in 2010.",
author = "Hiroshi Tsukamoto and Naoyasu Ueda and Takahiko Horiuchi",
year = "2011",
month = "11",
day = "9",
doi = "10.2177/jsci.34.361",
language = "English",
volume = "34",
pages = "361--368",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Progress in classification and treatment for TNF receptor-associated periodic syndrome

AU - Tsukamoto, Hiroshi

AU - Ueda, Naoyasu

AU - Horiuchi, Takahiko

PY - 2011/11/9

Y1 - 2011/11/9

N2 - TNF receptor-associated periodic syndrome (TRAPS) is an autosomal dominant autoinflammatory disorder characterized by recurrent febrile attacks. TRAPS is associated with mutation in the gene encoding TNF Receptor I (TNFRI) and seven mutations have been reported in Japan. Molecular modeling experiments indicate that the mutant TNFRI accumulates intracellularly in the endoplasmic reticulum due to misfolding and activates MAP kinase (MAPK) through induction of mitochondrial reactive oxygen species production. MAPK activation is further enhanced by the stimulation through toll-like receptor, resulting in the enhanced proinflammatory cytokine production. Febrile attacks last 21 days on average and occur every one to several months. Myalgia, erythematous macular rash, abdominal pain, conjunctivitis, periorbital edema, chest pain and arthralgia are commonly seen during the attacks. Glucocorticoid is effective in decreasing the severity and duration of the febrile attacks. Soluble TNF receptor etanercept, IL-1 receptor antagonist Anakinra TM and IL-6 receptor antagonist tocilizumab are effective in some patients. Japanese study group of TRAPS conducted national survey to make new diagnostic criteria in 2010.

AB - TNF receptor-associated periodic syndrome (TRAPS) is an autosomal dominant autoinflammatory disorder characterized by recurrent febrile attacks. TRAPS is associated with mutation in the gene encoding TNF Receptor I (TNFRI) and seven mutations have been reported in Japan. Molecular modeling experiments indicate that the mutant TNFRI accumulates intracellularly in the endoplasmic reticulum due to misfolding and activates MAP kinase (MAPK) through induction of mitochondrial reactive oxygen species production. MAPK activation is further enhanced by the stimulation through toll-like receptor, resulting in the enhanced proinflammatory cytokine production. Febrile attacks last 21 days on average and occur every one to several months. Myalgia, erythematous macular rash, abdominal pain, conjunctivitis, periorbital edema, chest pain and arthralgia are commonly seen during the attacks. Glucocorticoid is effective in decreasing the severity and duration of the febrile attacks. Soluble TNF receptor etanercept, IL-1 receptor antagonist Anakinra TM and IL-6 receptor antagonist tocilizumab are effective in some patients. Japanese study group of TRAPS conducted national survey to make new diagnostic criteria in 2010.

UR - http://www.scopus.com/inward/record.url?scp=80455162570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455162570&partnerID=8YFLogxK

U2 - 10.2177/jsci.34.361

DO - 10.2177/jsci.34.361

M3 - Article

C2 - 22041423

AN - SCOPUS:80455162570

VL - 34

SP - 361

EP - 368

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 5

ER -